Kinetic Time Courses of Bisphenol-S in Volunteers

NCT ID: NCT03340168

Last Updated: 2018-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-05

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The time course of bisphenol S in plasma and urine will be monitored in female adults exposed to a single oral and dermal dose of bisphenol-S. Six female will be recruited. Blood and urine will be collected at specified times post-treatment. Bisphenol concentrations will be measured in those samples.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a first step, volunteers will be exposed orally acutely to 0.1 mg / kg of body weight (bw) orally (corresponding to 7 mg for an individual of 70 kg). According to the recent assessment by the US Environmental Protection Agency (U.S. EPA), this dose is considered to be associated with no adverse effect for a subchronic exposure scenario in rats (EPA, 2014). The deuterated form of bisphenol S (BPS d8, Toronto Research Chemical) will be used to avoid potential interference with BPS in the diet. The dose that will be administered to volunteers (0.1 mg / kg bw) orally, in deuterated form, is identical to that previously used in a study in volunteers exposed to Bisphenol A (0.1 mg / kg of BPA-d6 administered oral in volunteers) (Thayer et al., 2015).

The BPS reference dose (RfD) was established based on a 45-day parental toxicity study in orally exposed male rats with No-Observed Adverse Effect Level (NOAEL) 10 mg / kg bw (Lowest-Observed-Adverse-Effect-Level (LOAEL) of 60 mg / kg bw / day for parental toxicity, and a NOAEL and LOAEL value of 60 and 300 mg / kg bw / day for reproductive toxicity) (EPA 2014) (page 4-282). The dose administered in volunteers will be 100 times lower than the NOAEL and consider an inter-species uncertainty factor of 10 and interindividual of 10. The six volunteers will then be exposed orally acutely to the previously determined dose (0.1 mg / kg bw).

For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.

In a second component, volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. It is important to note that there is currently no recommended reference dose for dermal exposure. Studies on the toxicokinetics of bisphenol A (BPA) in the animal and human model estimated that the absorption fraction was 8.6 ± 2.1% in human skin explants (n = 7) (Demierre et al. , 2012). The expected dermal administration dose assumes that dermal absorption is \<10% based on the Demierre study and therefore may be higher than the oral dose. Preliminary experience on a volunteer will be done before doing all the planned volunteers.

About 48 hours before dermal exposure to BPS, it is recommended to remove the hair on the forearm while taking care not to irritate the skin too much. The solution will then be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 µl for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).

The kinetics of bisphenol S (BPS) and its metabolite (glucurono-conjugated BPS (BPSG) in blood will be documented by collecting blood by venous puncture at time: -30 min (control sample) and at fixed times during a 48-h period post-treatment: at 15 min, 30 min, 45 min, 1 h, 1 h 15, 1 h 30, 1 h 45, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 24 h and 48 h post-treatment (n = 17 samples per individual). A catheter will be inserted during the day of exposure, to allow serial blood sampling. A total of 20 ml will be collected per time point, which represent a total of 340 ml, which is inferior to a blood donation.

To document urinary time cours, complete urine voids will be collectedin distinct bottles at fixed time periods: -10 h-0 h (control) and 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h, 12-14 h, 14-24 h, 24-48 h and 48-72 h post-administration (n = 11 collections per individual and all void between two time points will be pooled).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PHARMACOKINETICS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bisphenol-S kinetics - oral exposure

Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.

Group Type EXPERIMENTAL

Bisphenol-S

Intervention Type OTHER

Oral and dermal exposure in volunteers

Bisphenol-S kinetics - dermal exposure

volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).

Group Type EXPERIMENTAL

Bisphenol-S

Intervention Type OTHER

Oral and dermal exposure in volunteers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bisphenol-S

Oral and dermal exposure in volunteers

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female

Exclusion Criteria

* People with liver or kidney problems or cancer
Minimum Eligible Age

25 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université de Montréal

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michèle Bouchard

Full professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michèle Bouchard, PhD

Role: PRINCIPAL_INVESTIGATOR

Université de Montréal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Université de Montréal

Montreal, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michèle Bouchard, PhD

Role: CONTACT

5143436111 ext. 1640

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michèle Bouchard, PhD

Role: primary

5143436111 ext. 1640

Jonathan Côté, MSc

Role: backup

5143436111 ext. 2374

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EST-17-174

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

18794 - Human Photo Toxicity Test
NCT02751372 COMPLETED NA